A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

Also called NCT04605991

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 187 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04605991
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04605991. Allocation not applicable; no masking; primary purpose treatment. Start 2020-11-04 (actual); primary completion 2022-02-04 (actual). Results posted on 2023-03-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
Intervention (Drug)
LY900014
Intervention (Drug)
Insulin Glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04605991
Content hash
4d6ce16258c64db236e30d8cdf4e275acfae0a12f8df808b997563602bbcca52